The inhibitory effect of ursodeoxycholic acid and pentoxifylline on platelet derived growth factor-stimulated proliferation is distinct from an effect by cyclic AMP

Immunopharmacology

Volumn 39, Issue 3, 1998, Pages 181-191

  Peterson, Theresa C ^a   Slysz, Gordon ^a   Isbrucker, Richard ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

C kinase inhibitor; Cyclic AMP; Fibroblasts; Fibroproliferation; H 7; Pentoxifylline; Platelet derived growth factor; Ursodeoxycholic acid

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 2',3' DIDEOXYADENOSINE; BUCLADESINE; CYCLIC AMP; DRUG METABOLITE; PENTOXIFYLLINE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C INHIBITOR; TAUROURSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MYOFIBROBLAST; PRIORITY JOURNAL; SKIN FIBROBLAST;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANTIMETABOLITES; BUCLADESINE; CELL DIVISION; CELLS, CULTURED; CHOLAGOGUES AND CHOLERETICS; CYCLIC AMP; DIDEOXYADENOSINE; DRUG INTERACTIONS; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; PENTOXIFYLLINE; PLATELET-DERIVED GROWTH FACTOR; STIMULATION, CHEMICAL; TAUROCHENODEOXYCHOLIC ACID; TETRAZOLIUM SALTS; THIAZOLES; URSODEOXYCHOLIC ACID;

EID: 0032096334     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(98)00021-6     Document Type: Article

References (44)

1. Alonso C., Gamundi S., Castillo G., Orce G., Coviello A. Inhibitory effect of sodium ursodeoxycholate on basal and stimulated short circuit current across the isolated toad skin. Comp. Biochem. Physiol., Pharmacol. Toxicol. Endocrinol. 110(3):1995;321-327.
2. Bouscarel B., Eryaka S., Gettys T., Fromm H., Noonan F. Alteration of cyclic AMP mediated hormonal responsiveness by bile acids in cells of a non hepatic origin. American Journal of Physiology. 268(6):1996;G908-G916. Part 1.
3. Calmus Y., Guechot J., Podevin P., Bonnefis M., Giboudeau J., Poupon R. Differential effects of chenodeoxycholic and ursodeoxycholic acids in interleukin 1, interleukin 6 and tumor necrosis factor-α production by monocytes. Hepatology. 16:1992;719-723.
4. Coleman R., Iqbal S., Godfrey P.P., Billington D. Composition of several mammalian biles and their membrane damaging properties. Biochem. J. 178:1979;201-208.
5. Crouch S., Fletcher J. Effect of ingested pentoxifylline on neutrophil superoxide anion production. Infect. Immun. 60:1992;4504-4509.
6. Denizat F.S., Lang R. Rapid colorimetric assay for cell growth and survival. J. Immunol. Meth. 89:1986;271-277.
7. Dohlman J.G., Payan D.G., Goetzl E.J. Generation of a unique fibroblast activating factor by human monocytes. Immunology. 52:1984;577-584.
8. Failli P., Ruocco C., De-Franco R.et al. The mitogenic effect of PDGF in human hepatic stellate cells requires calcium influx. Am. J. Physiol. 269:1995;C1133-C1139.
9. Friedman S.L. The cellular basis of hepatic fibrosis mechanisms and treatment strategies. N. Engl. J. Med. 328:1993;1828-1835.
10. Heathcote E.J., Cauch-Dudek K., Walker V., Bailey R., Blendis L., Ghent C., Michieletti P., Minuk G., Pappas S., Scully L., Steinbrecher U., Sutherland L., Williams C., Witt-Sullivan H., Worobetz L., Milner R., Wanless I. The Canadian multicentre double blind randomised controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 19:1994;1149-1156.
11. Isbrucker R., Peterson T.C. Collagens α(I) and α(III) mRNA levels are increased in a porcine model of hepatic fibrosis and reduced by pentoxifylline administration. Gastroenterology. 106:1994;1086A.
12. Isbrucker R., Peterson T.C. Platelet-derived growth factor and pentoxifylline modulation of collagen synthesis in myofibroblasts. Toxicol. Appl. Pharmacol. 149:1998;120-126.
13. Marra F., Pinzani M., DeFranco R., Laffi G., Gentilini P. Involvement of phosphatidylinositol 3-kinase in the activation of extracellular signal-regulated kinase by PDGF in hepatic stellate cells. FEBS Letters. 376:1995;141-145.
14. Meskini N., Nemoz G., Okyayuz-Baklouti I., Lagarde M., Prigent A.F. Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation. Biochem. Pharmacol. 47:1994;781-788.
15. Park T.J., Kim K.T. Cyclic AMP independent inhibition of voltage-sensitive calcium channels by forskolin in PC12 cells. J. Neurochem. 66(1):1996;83-88.
16. Peterson T.C. Pentoxifylline prevents hepatic fibrosis in an animal model. Clin. Invest. Med. 15:1992;A64. Suppl. A.
17. Peterson, T.C., 1992. Modes of communication between Kupffer cells and hepatocytes under normal and pathological conditions. In: Billiar, T., Curran, R. (Eds.), Hepatocyte and Kupffer Cell Interactions, Chap. 2. CRC Press, Boca Raton.
18. Peterson T.C. Pentoxifylline prevents fibrosis in an animal model and inhibits platelet derived growth factor driven proliferation of fibroblasts. Hepatology. 17:1993;486-493.
19. Peterson T.C. Inhibition of fibroproliferation by pentoxifylline: activity of metabolite-1 and lack of a role of adenosine receptors. Biochem. Pharmacol. 52:1996;597-602.
20. Peterson T.C., Huet P.M. Role of PDGF, TGFβ and TNFα in fibroproliferation stimulated by PBC patient sera samples. Can. J. Gastroenterol. 10(40a):1996;S78.
21. Peterson T.C., Isbrucker R.A. Role of interleukin-1β and PDGF in the AHH depressive and fibrogenic activity of MCM from patients with liver disease. J. Leuk. Biol. 52A:1990;. Suppl. 1.
22. Peterson T.C., Isbrucker R.A. Anti-human PDGF inhibits fibrogenic activity of MCM from patients with liver disease. Hepatology. 12:1990;909A.
23. Peterson T.C., Isbrucker R.A. Inhibition of PDGF driven fibroproliferation. Cytokine. 3(5):1991;502A.
24. Peterson T.C., Isbrucker R.A. Fibroproliferation in liver disease: role of monocyte factors. Hepatology. 15:1992;191-197.
25. Peterson T.C., Neumeister M. Effect of pentoxifylline in rat and swine models of hepatic fibrosis: role of fibroproliferation in its mechanism. Immunopharmacol. 31:1996;183-193.
26. Peterson, T.C., Robertson, H.A., 1997. PDGF upregulates c-fos and c-jun gene expression: selective inhibition of c-jun by pentoxifylline. Cytokine.
27. Peterson T.C., Isbrucker R., Hooper M. In vitro effect of platelet derived growth factor on fibroproliferation and effect of cytokine antagonists. Immunopharmacology. 28(3):1994;259-270.
28. Pinzani M., Weber F.L., Gesualdo L., Abboud H.E. Expression of PDGF in an in vivo model of acute liver inflammation. Hepatology. 12:1990;920A.
29. Pinzani M., Milani S., Grappone C., Weber F., Gentilini P., Abboud H. Expression of platelet derived growth factor in a model of acute liver injury. Hepatology. 19:1994;701-707.
30. Pinzani M., Marra F.et al. Inhibition by pentoxifylline of extracellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cells. Br. J. Pharmacol. 119:1996;1117-1124.
31. UDCA-PBC Study Group, Poupon R.E., Balkau B., Eschwege E., Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N. Engl. J. Med. 324:1991;1548-1554.
32. UDCA-PBC Study Group, Poupon R.E., Poupon R., Balkau B. Ursodiol for the long term treatment of primary biliary cirrhosis. N. Engl. J. Med. 330:1994;1342-1347.
33. Preaux A.M., Mallat A., Rosenbaum J., Zafrani E.S., Mavier P. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology. 26:1997;315-322.
34. Reims A., Poirier J., Lecoz F., Midavaine M., Lecocq B., Grange J., Poupon R., Cheymol G., Jaillon P. Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin. Pharmacol. Therapeutics. 47:1990;354-359.
35. 2 receptors on rat Kupffer cells. Hepatology. 19:1994;1445-1452.
36. Ross, R., Bowen-Pope, D.F., Raines, E.W. Platelet derived growth factor and its role in health and disease. Phil. Trans. R. Soc. Lond. B, Vol. 327, pp. 155-169.
37. Rudi J., Waldherr R., Raedsch R., Commerell B. Hepatocyte proliferation in primary biliary cirrhosis as assessed by proliferating cell nuclear antigen and KI-67 antigen labelling. Journal of Hepatology. 22(1):1995;43-49.
38. Steihl A., Rudolph G., Raedsch R., Moller B., Hopf U., Lotterer E., Bircher J.et al. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in primary biliary cirrhosis. Hepatology. 12:1990;492-497.
39. Turjman, N., Nair, P.P., 1988. Tissue bound bile acids. In: Setchell, K.D.R., Kritchevsky, D., Nair, P.P. (Eds.), The Bile Acids: Chemistry, Physiology and Metabolism. Plenum Press, New York, pp. 373-378.
40. Vouristo M., Farkkila M., Karvonen A.et al. A placebo controlled trial of primary biliary cirrhosis. Treatment with colchicine and ursodeoxycholic acid. Gastroenterology. 108(5):1995;1470-1478.
41. Ward A., Clissold S.P. Pentoxifylline, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs. 34:1987;50-97.
42. Wu J., Dent P., Jelinek T., Wolfman A.et al. Inhibition of the EGF activated Map kinase signalling pathway by adenosine 3,5-monophosphate. Science. 262:1993;1065-1069.
43. Yoshikawa M., Tsujii T., Matsumura K., Yamao J., Matsumura Y., Kubo R., Fukui H., Ishizaka S. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology. 16:1992;358-364.
44. Zar, J.H., 1974. Biostatistical Methods. Prentice-Hall, Englewood Cliffs, NJ.